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Abstract
Disorders such as chronic fatigue syndrome (CFS) and gulf war syndrome (GWS) are characterised by prolonged fatigue and
a range of debilitating symptoms of pain, intellectual and emotional impairment, chemical sensitivities and immunological
dysfunction. Sudden infant death syndrome (SIDS) surprisingly may have certain features in common with these conditions.
Post-infection sequelae may be possible contributing factors although ongoing infection is unproven. Immunological
aberration may prove to be associated with certain vasoactive neuropeptides (VN) in the context of molecular mimicry,
inappropriate immunological memory and autoimmunity.
Adenylate cyclase-activating VNs including pituitary adenylate cyclase-activating polypeptide (PACAP), vasoactive
intestinal peptide (VIP) and calcitonin gene-related peptide (CGRP) act as hormones, neurotransmitters, neuroregulators,
immune modulators and neurotrophic substances. They and their receptors are potentially immunogenic. VNs are widely
distributed in the body particularly in the central and peripheral nervous systems and have been identiﬁed in the gut, adrenal
gland, blood cells, reproductive system, lung, heart and other tissues. They have a vital role in maintaining cardio-respiratory
function, thermoregulation, memory, concentration and executivefunctions such as emotional responses including social cues
and appropriate behaviour. They are co-transmitters for a number of neurotransmitters including acetylcholine and gaseous
transmitters, are potent immune regulators with primarily anti-inﬂammatory activity, and have a signiﬁcant role in protection
of the nervous system against toxic assault as well as being important in the maintenance of homeostasis.
This paper describes a biologically plausible mechanism for the development of certain fatigue-related syndromes based on
loss of immunological tolerance to these VNs or their receptors following infection, other events or de novo resulting in
signiﬁcant pathophysiology possibly mediated via CpG fragments and heat shock (stress) proteins. These conditions extend
the public health context of autoimmunity and VN dysregulation and have implications for military medicine where
radiological, biological and chemical agents may have a role in pathogenesis. Possible treatment and prevention options are
considered.
Keywords: Adenylate Cyclase, autoimmunity, chronic fatigue syndrome (CFS), gulf war syndrome, sudden infant death
syndrome (SIDS), vasoactive neuropeptides
Introduction
Endogenous adenylate cyclase (AC)-activating vaso-
active neuropeptides (VNs) may be implicated in
causing some fatigue-related conditions currently
having no established explanation such as chronic
fatigue syndrome (CFS), Gulf War syndrome (GWS),
ﬁbromyalgia and even sudden infant death syndrome
(SIDS) (Staines 2004a,b,c). This family of VNs
includes pituitary adenylate cyclase-activating
polypeptide (PACAP), vasoactive intestinal peptide
(VIP) and calcitonin gene-related peptide (CGRP).
The possible role of endogenous VN autoimmunity in
these conditions is a novel but unproven concept.
This paper reviews evidence for these conditions
resulting from possible immune dysfunction or other
pathologies associated with VNs or their receptors.
Causes of these aberrations may include a range of
insults such as infection, chemical and biological
agents, radiological and physical and psychological
stressors including trauma. The hypothesis is explored
that infections, possibly exhibiting molecular mimicry
with these VNs, or alternatively VN responses from
any cause, may provoke adverse autoimmune sequelae
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expression. While some of these conditions may
resolve over time, others may have catastrophic (e.g.
SIDS) or long-term sequelae. Variations in outcomes
may relate to the degree of long-term perverse
immunological events.
This paper also proposes that autoimmune dysfunc-
tion of these VNs may represent a family of disorders
mediated by signiﬁcant pathophysiology such as neu-
ronal apoptosis via dysregulation of key biochemical and
epigenetic pathways which may be mediated in part by
CpG DNA fragments and heat shock (stress) proteins.
Vasoactive neuropeptide roles and functions
AC-activating VNs have signiﬁcant commonality
between species and are strongly preserved in
evolutionary terms indicating their crucial roles for
survival. Substantial amino acid sequence homology
exists between them, suggesting evolution from
a common ancestral gene, and they demonstrate
somedegreeofoverlapofstructureandfunctionaswell
as potential for immunological cross-reactivity. These
VNs belong to the secretin-glucagon super-family,
exertingsigniﬁcantcontrolovercarbohydrateandlipid
metabolism. They have important roles in vasodila-
tion, neurotrophism, nociception, neuroregulation
and neurotransmission including thermoregulation,
cardio-respiratory control, balance and vestibular
function, emotional and intellectual functioning
including memory and concentration, and immuno-
logical and hormonal modulation.
They exert their effects at high level in controlling
central and peripheral nervous systems and hypothala-
mic–pituitary–adrenal axis functions. Other vital
functions regulated in the brain include olfaction,
feedingandreproductivebehaviours,circadianrhythm,
and sleep–wake cycles. They and their receptors are
expressed at important peripheral sites such as heart,
gut, blood, lung, pancreas, liver and urogenital systems
(Ishizuka et al. 1992, Arimura 1998, Sherwood et al.
2000, Hannibal 2002, Hashimoto 2002, Ganea et al.
2003). Compromise of their function is likely to have
serious consequences for homeostasis.
Endogenous opioid activity is functionally related to
cytokine and VN activity suggesting that pain
mediation and perception may be altered in conditions
where endogenous opioid function is impaired
through VN mechanisms (Wilderman and Armstead
1997, Peterson et al. 1998). Nitric oxide (NO)
metabolism is implicated in immunomodulation as
well as possibly mediating chemical sensitivity in these
conditions suggesting a plausible mechanism for some
concurrent symptoms in CFS and GWS (Pall 2002,
Onoue et al. 2002). Synaptic plasticity and pain
behaviours are critically mediated by CGRP in the
amygdala (Han et al. 2005).
VNs inﬂuence receptor accumulation and activity
for acetylcholine (Fahrenkrug and Hannibal 2004)
and other neurotransmitters including carbon mon-
oxide (CO) (Watkins et al. 2004) and NO (Parsons
et al. 2005). PACAP is co-located with vesicular
acetylcholine transporter in nerve terminals in all
mouse adrenomedullary cholinergic synapses (Hame-
link et al. 2002) and CGRP is known to induce
acetylcholine receptor expression in rat soleus muscle
(Buffelli et al. 2001). There is a known association of
VPAC2 receptors with acetylcholine and muscle
function (Hinkle et al. 2005).
A number of neurotransmitters are inﬂuenced by
VNs and include the adrenergic, noradrenergic,
cholinergic, histaminergic, GABA-ergic, glutamater-
gic, dopaminergic and serotonergic systems (Sandvik
et al. 2001, Shintani et al. 2003). VIP and PACAP
receptors have been demonstrated in guinea pig
cerebral cortex and have substantial effects on cyclic
adenosine monophosphate (cAMP) production
(Zawilska et al. 2005) and PACAP is known to have
a potentiating additive effect with adrenaline and
noradrenaline on cAMP production in rat cerebral
cortex indicating a crucial role in neuroregulation
(Nowak and Kuba 2002).
Much central nervous system processing is under
VN control to a greater or lesser extent and co-
transmitter functions may be a linkage to fatigue
mediation and a range of other symptoms in these
syndromes. In addition to those functions listed
above, high level CNS processes may become
compromised in VN disorders including executive
functions such as ensuring appropriate behaviours and
response to social cues, irritability, emotional lability,
planning for the future, empathy and relationship
building, verbal skills in problem solving and so on.
This would suggest involvement of neuronal connec-
ting pathways between basal ganglia, limbic system of
hippocampus and amygdala and pre-frontal and
frontal cortices as these pathways are sensitive to
compromise (Arnsten and Li 2005).
VNs are mediated by G protein-coupled receptors
(GPCR). The secondary transmitter cAMP is
generated from adenosine triphosphate (ATP) via
AC which is known to exist in multiple isoforms and
exhibits a range of processing functions (Nowak and
Zawilska 1999), therefore, defects of AC activation
will result in impaired cAMP production. VNs operate
via multiple signaling processes (Zhou et al. 2002) and
have complex interactions with a wide range of
neurotransmitters including cross-talk feedback and
control mechanisms. Hence, treatment for postulated
fatigue-related conditions might include upstream
reactivation of cAMP or downstream inhibition of
cAMP breakdown (see below).
SIDS may be the manifestation of an acutely
acquired autoimmune response to these VNs. Recent
minor infection, breathing position and the presence
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may all contribute to loss of immunological tolerance
to these VNs or their receptors. This would have
potentially catastrophic consequences for cardio-
respiratory centres in the brain stem as well as the
heart. PACAP, for example, is a powerful respiratory
stimulant (Runcie et al. 1995) suggesting vulnerability
to respiratory compromise. PACAP-deﬁcient mice
suffer sudden neonatal death attributed to respiratory
control defects, raising the possibility of VN dysfunc-
tion as a potential cause of SIDS (Cummings et al.
2004). Early recognition of potential vulnerability to
SIDS, for example, will be of special interest and may
contribute to the development of preventive strategies.
Endogenous VNs exert a wide spectrum of
immunological functions and have a critical role in
homeostasis of neuronal and immune systems through
a number of pathways including inhibition of
chemokine production in activated microglia. Distur-
bances in their function are recognised as potential
causes of autoimmune disease and they appear to have
a role in protecting bystander lysis, a process in the
pathogenesis of several autoimmune and inﬂamma-
tory diseases (Delgado et al. 2002). VNs have a role in
maintaining peripheral tolerance by generating tolero-
genic dendritic cells (Delgado et al. 2005).
VIP is known to prevent experimental autoimmune
uveoretinitis (Keino et al. 2004). PACAP is known to
ameliorate experimental autoimmune encephalomye-
litis (Kato et al. 2004) and hypoxia (Suk et al. 2004)
demonstrating its neuro-protective role. In animal
models of EAE, sympathetic nervous system regu-
lation mediated through Th1 cells is signiﬁcantly
promoted by certain other neurotransmitters, e.g.
neuropeptide Y (NPY) (Bedoui et al. 2003).
PACAP and VIP exert an extraordinary array of
functions in the brain and other organs and peripheral
tissues. VIP has been identiﬁed in all regions of the
brain including cerebral vessels (Fahrenkrug et al.
2000) indicating susceptibility to vasodilatory
dysfunction. Neurovascular coupling in vasoactive
pathways is mediated via GABA (Cauli et al. 2004).
Balance and vestibular functions are regulated by
VNs, e.g. CGRP (Kong et al. 2002) and this may have
a vascular component (Lyon and Payman 2000). VIP
is produced and released by intrinsic neurons in the
heart and improves cardiac perfusion and function
(Dvorakova et al. 2005). Hence, the vasodilatory role
of VNs will be an important function lost through VN
failure and may explain a signiﬁcant extent of the
pathophysiology in these conditions by giving rise to
hypoperfusion and ischemia.
The role of VNs in protecting the brain from
apoptosis is well documented (Falluel-Morel et al.
2004). Apoptosis is known to be higher in SIDS cases
than controls with hippocampus and brainstem,
including dorsal nuclei, being affected (Waters et al.
1999) and apoptotic neurodegeneration is postulated
as the speciﬁc pathophysiological mechanism in SIDS
(Sparks and Hunsaker 2002).
Mechanisms associated with apoptosis would,
therefore, indicate a suitable area for investigation,
particularly those mechanisms usually protective
against apoptosis. These roles are fulﬁlled by VNs,
for example, ischaemia induced apoptosis in the rat
hippocampus is protected by PACAP through
inhibition of the JNK/SAPK and p38 signalling
pathways (Dohi et al. 2002) and PKA and phospha-
tidylinositol 30-OH kinase pathways demonstrate
neuroprotective roles in cerebellar granule neurons
(Bhave and Hoffman 2004). PACAP is also known to
have a neuroprotective effect against a range of
insults. Ethanol-induced apoptosis occurs via caspase
pathways resulting in DNA fragmentation, mitochon-
drial permeability and cell death. PACAP, acting via
its receptor PAC1, protects against ethanol-induced
cell death and may have a therapeutic role in
conditions such as fetal alcohol syndrome (Vaudry
et al. 2002).
Late-gestation blockade of VIP activity in pregnant
mice has shown distinct morphological abnormalities
in the somatosensory cortex of offspring and their
response to hypoxia being subsequently impaired.
A signiﬁcant arousal deﬁcit was seen in anti-VIP mice,
which was not associated with deranged peripheral or
brainstem-mediated responses to hypoxia during
sleep (Cohen et al. 2002). Compromise of VN
function, therefore, has likely major respiratory
consequences. This ﬁnding may have signiﬁcant
implications for infection in mothers of SIDS victims
prior to birth.
Cardiovascular function is in part regulated by VNs.
Some variation in the cardiac roles of PACAP exists
and is dose dependent, for example, PACAP may
promote both tachycardia and bradycardia (Chang
etal.2005).PACAPactivatesintracardiacpostganglio-
nic parasympathetic nerves by shortening the effective
refractory period, and has a greater proﬁbrillatory
effect than vagal stimulation (Hirose et al. 2001).
Neuroexcitability in intracardiac neurons depends on
PAC1 receptor activation (DeHaven and Cuevas
2004). Conceivably PACAP opposition, for example,
through autoimmune effects on the PAC1 receptor
might, therefore, result in decreased cardiac
responsiveness.
Brownadipose tissue metabolism and thermal stress
have been linked to SIDS. Neonatal adipose tissue is a
primary site of cytokine and cytokine receptor action
(Gray et al. 2002) and metabolism is a noradrenaline-
cAMP-proton pump system. While the precise
mechanism of brown adipose tissue metabolism
dysfunction is unclear, a combination of factors
including metabolic stress, infection, necrosis and
vascular hypoperfusion has been suggested (Stephen-
son and Variend 1987). Hence, VN failure may be
mediated through these pathways in SIDS.
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The development of autoantibodies to PACAP and
VIP in mammalian tissues suggests that immunologi-
cal tolerance may be readily broken. It has been
postulated that depletion of VIP by speciﬁc antibodies
in autoimmune disease may interfere with VIP
regulation of T cells and inﬂammatory cells and result
in further ampliﬁcation of autoreactive immunological
responses (Bangale et al. 2002). Also, as VIP receptors
are expressed on T-lymphocytes, VIP could directly
affect cytokine production and proliferation of
T-lymphocytes (Johnson et al. 1996).
Some researchers have found aberrations of the
oligoadenylate synthetase pathway, a key ATP-
associated RNase L-mediated antiviral mechanism,
in CFS (Nijs and De Meirleir 2005). The oligoade-
nylate system is considered a major regulator of cell
metabolism including cell growth and differentiation,
oncogenic stability and apoptosis in addition to
antiviral functions (Mykhailyk et al. 2003). This
pathway is inﬂuenced by VIP (Chelbi-Alix et al. 1991)
and cAMP (Itkes 1994) suggesting possible dysregula-
tion with VN compromise.
Autoimmune dysfunction of VNs or their receptors
might arise via a number of pathways. Cytosine-
guanosine dinucleotide DNA (CpG) fragments are
immuno-stimulating or suppressing sequences which
may exist in promoter regions of VN receptors and be
vulnerable to assault mechanisms such as hypomethy-
lation, resulting in dysregulation of transcriptional/
translational capacity. (Pei and Melmed 1995, Lutz
et al. 1999). CpG mechanisms may also control
secretin gene expression through methylation mecha-
nisms (Lee et al. 2004, Pang et al. 2004) and
methylation of gene promoters may have a role in
calcitonin/alpha CGRP gene regulation (Broad et al.
1989). The PACAP receptor gene is known to be
G þ C rich (Aino et al. 1995).
Antibody responses to VNs or VN receptors might
hypothetically occur, giving rise to IgM or IgG
antibody types, resulting in short or long term
autoimmunity to these vital substances. Such mecha-
nisms might also result from mimicry with bacterial
residues, giving rise to mistaken recognition of self
VN-CpG for bacterial CpG and perverse VN
autoimmunity. CpG elements are known to be potent
stimulators of immune responses (Krieg 2003).
Heat shock proteins (HSPs) or stress proteins may
also play a role in VN autoimmunity or dysfunction.
These are important chaperone molecules for proper
intracellular functioning of VNs and are known to
have a key role in immunoregulation (Srivistava
2002). Moreover, HSPs and CpG are mutually
engaged in CpG signalling and recognition (Band-
holtz et al. 2003) suggesting that dysfunction or
compromise of one may result in compromise of the
other, with resulting compromise of VN function
(Staines 2005d,e).
High level and intricate homeostasis maintenance
appear to be hallmark functions of VNs. As noted
above they and their receptors are thought to be
immunogenic and are implicated in a range of
inﬂammatory and autoimmune conditions. They
also have complex self-regulatory mechanisms invol-
ving autoantibody catalysis. The pleiotropic pheno-
typic presentation of postulated VN autoimmune
disorders may reﬂect the multiplicity of pathogeneses
resulting from ligand and receptor diversity.
VN receptors are predominantly G-protein coupled
receptors (GPCR) being heterotrimeric seven trans-
membrane helical structures which control intracellu-
lar functioning mostly via cAMP through a number of
kinases and related pathways (Vaudry et al. 2000).
They and their receptors are widely and commonly
distributed through all species and function in
remarkably similar ways. As also noted above they
exert stimulatory and inhibitory inﬂuence on AC,
a vital step in cyclic AMP metabolism.
Functional redundancy of these substances and
their receptors is limited. Despite high evolutionary
preservation of VNs and a high degree of commonality
in peptide structure and amino acid sequencing there
are only three known receptor types for PACAP and
VIP namely PAC1, VPAC1 and VPAC2. It is
proposed that this relative lack of functional redun-
dancy makes them vulnerable and susceptible to
compromise from different causes resulting in diverse
clinical conditions. Autoimmune dysfunction of
GPCRs is known but not widely documented.
However, some studies have shed some light on
autoimmune and toxic processes affecting GPCRs.
Also molecular mimicry effects have been documen-
ted between some toxins, venoms and infections and
VN receptors and are probably due to cross-reactive
epitopes (Holz and Habener 1998, Goetzl et al. 2004).
Failure of constitutive or expressed activity of
GPCRs may be at the heart of VN autoimmune
disorders. The multi-functioning nature of GPCRs
and consequent cAMP activation pathways suggest
vulnerability to compromised function. These recep-
tors are capable of exhibiting agonism, antagonism
and inverse agonism having both stimulatory and
inhibitory roles and acting through complex mecha-
nisms (Milligan 2003). Mutations in receptor struc-
ture modify their function (Cao et al. 2000). VN
autoimmune disorders may prove to operate by
aberrant GPCR signaling via these mechanisms
(Staines 2005f).
Autoantibodies are found to nuclear and stress
proteins (Ro52 and Grp78) in Sjogren’s syndrome
(SS) (Gordon et al. 2001) and this association is
postulated to induce an autoimmune cascade in
other conditions (Purcell et al. 2003). Structural
similarities with some neuropeptides may suggest their
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Human muscarinic acetylcholine receptor (mAChR)
antibodies from SS sera increase cerebral NO synthase
activity and NO synthase mRNA levels in rat frontal
cortex indicating central parasympathetic functional
deregulation (Reina et al. 2004).
Antibodies to mAChR have been identiﬁed in CFS
patients (Tanaka et al. 2003a) and autoimmunity to
neurotransmitter receptors is also implicated in some
psychiatric disorders (Tanaka et al. 2003b) indicating
that receptor autoimmunity may result in both primary
and secondary psychiatric disorders consequent to
receptor pathology. These examples illustrate the multi-
faceted and complex roles of VNs and their receptors in
neuro-physiology, neuropsychology and autoimmunity.
Genomic expression of null receptor types may play
a role in VN autoimmune disorders. Receptors of the
“hip” variety are believed to be null variant or fail to
transduce signals despite normal ligand binding
properties (Zhou et al. 2002). Selective over-
expression ofthese receptorsdue todefects ingenomic
expression control may effectively reduce opportu-
nities for proper signal transduction. Alternatively,
blocking of otherwise normally transducing receptors
by pathogenic autoantibodies may simply block signal
transduction perhaps analogouslyto myastheniagravis
(MG). As these antibodies may be polyclonal with
varying degrees of blocking capacity, this may explain
heterogeneity in phenotypic expression of VN auto-
immune fatigue disorders. In other words fatigue
disorders of varying degrees of severity and duration
may result.
CpG DNA methylation disorders are being con-
sidered as possible causes of neuronal pathology (Iliev
et al. 2004). These fragment sequences in mammals
are usually methylated and lower in frequency
compared with bacterial DNA which are hypomethy-
lated and higher in frequency. In evolutionary
terms this represents a “friend or foe” detection
system (Goldberg et al. 2000). However, evolutionary
residues in mammals have regions reﬂecting more
bacterial characteristics and which are prone to
hypomethylation and may predispose to autoimmune
phenomena.
Disruption of usual DNA translation mechanisms
or epigenetic phenomena associated with these CpG
DNA fragments are possible innate sources of
auotoimmune reactivity as well as other immunomo-
dulatory responses. VN receptor autoimmunity might
conceivably result from perverse immunological
memory induced via HSPs or cytosine-guanine
(CpG) DNA dinucleotide fragments if directed
against the VNs or their receptors. As relative over-
expression and under-expression of genomic VN or
receptor characteristics may be indicated both
immunostimulatory and immunosuppressive CpG
fragments may have applications in treatment and
prevention and are considered further below.
An intriguing alternative hypothesis is that involving
VN receptor desensitisation. Several studies have
shown that PAC1 and VPAC receptors undergo
homologous desensitisation when pre-exposed to their
respective ligands. This mechanism is mediated in
retinoblastoma cells via GPCR kinase3 and PKC but
not PKA mechanisms (Dautzenberg and Hauger
2001). As noted above, VNs are known to be self-
regulated by respective antibodies and catalytic
mechanisms. VN fatigue-related disorders may result
from loss of control over this neurotransmitter-
regulating desensitising mechanism, as it is usually a
reversible physiological process. But it is also one
subject to impairment depending on other impacting
factors such as xenobiotics, infection, immune
dysregulation and so on.
Consequences of these anti-receptor mechanisms
would be potentially serious as there would be
uncoupling of the activity-dependence mechanism
which routinely provides potentiation of the AC
second messenger system. Pre-synaptic facilitation
may be impaired resulting in signiﬁcant enhancement
or exacerbation of the desensitising mechanism.
Uncoupling of activity dependency might then
occur. Thus, the role of AC as a “coincidence
detector” to engage G receptors may be lost. Retro-
grade signaling may also then be impaired to the pre-
synaptic cell resulting in false messages being relayed
and VN release excessively prolonged. Interestingly
“class-switching” between G stimulatory and G
inhibitory receptors occurs (Halls et al. 2005) and
this may also explain GPCR dysfunction.
Loss of this functionality may also result in loss of
associativity which normally enhances the efﬁciency of
this messaging system. While both inhibitory and
stimulatoryGPCR receptorcomponentsinﬂuence AC
activity, desensitisation mechanisms may operate
anomalously. The voltage gated calcium channels of
L-, N- and P/Q-types appear affected (Hayashi et al.
2002). Hence this proposed mechanism may be
crudely analogous to Lambert-Eaton syndrome
(LES) and autoimmune impairment of calcium
channels (Waterman 2001).
Dysregulation of multiple complex biochemical
pathways
Multiple complex biochemical pathways are mediated
by AC-activating VNs. Some key pathways are
considered below. Effector pathways for apoptosis
are considered along with glutamate metabolism as a
model for dysregulation of vital neurotransmitter and
biochemical mechanisms postulated in VN auto-
immune disorders. These pathways exemplify mecha-
nisms operating in conditions of cellular and somatic
stress within and beyond the central nervous system
(Staines 2005a).
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response to certain stimuli (Norrholm et al. 2005).
Delgado (2002) reports inhibition of the MEKK1/
MEK4/JNK pathway, leading to a reduction in
phosphorylated c-Jun and stimulation of JunB,
mediated through the VPAC1 receptor via the
cAMP/PKA pathway. VIP/PACAP interference with
the stress-induced SAPK/JNK pathway in activated
microglia may thus represent a signiﬁcant element in
the regulation of inﬂammatory responses in the CNS
by endogenous VNs.
Dysregulation of dehydroepiandrosterone (DHEA)
metabolism has been noted in CFS (Maes et al. 2005,
Cleare et al. 2004) and abnormal responses to ACTH
occurs indicating inappropriate responses to stress
(Scott et al. 2000). PACAP has a stimulatory effect on
steroid secretion including cortisol and DHEAS in the
adrenal gland and is mediated via catecholamines
(Breault et al. 2000). VIP also is involved in ACTH-
independent regulation of steroidogenesis in adrenal
(tumour) cells (Haidan et al. 1998).
PACAPand VIPare potent neurotrophic substances
and play a vital role in neuronal survival (Shioda et al.
1998). PACAP inhibits apoptosis in many tissues
including cerebellar granule cells by inhibition of
caspase-3, and mitochondrial pathways play a pivotal
role in these anti-apoptotic effects. Ceramide (C2)
mitochondrial potential inhibitory effects mediated via
caspase systems together with cytochrome c release
from mitochondria are countered via PACAP in
apoptosis. PACAP acts by strongly inhibiting C2-
ceramide-inducedactivationofcaspase-3(Vaudryetal.
2003, Falluel-Morel et al. 2004). Ceramide-induced
apoptosis is also inhibited in PC12 cells by PACAP by
affecting signaling downstream of JNK activation
(Hartﬁeld et al. 1998). Moreover, PACAP has been
shown to stimulate MAPK in both PKA- and PKC-
independentmanner inastrocytes(Morooetal.1998).
VIP also inhibits translocation of cytochrome c from
mitochondriainhippocampalcellsinprotectingagainst
apoptotic cell death (Antonawich and Said 2002).
Hence, the implications for VN failure are serious as
PACAP/VIP play a critical role in mitochondrial and
other pathways in protecting against apoptosis.
Complex biochemical pathways intersect immune
and neurotransmitter functions and are modulated by
VNs and glutamate serves as a useful model. For
example, exposure to ammonia during prenatal and
lactation periods results in long-lasting impairment of
N-methyl-D-aspartate (NMDA) receptor function
which may be associated with altered aspartate
amintotransferase activity (Minana et al. 1995) and
hence altered glutamate function which may be
relevant in SIDS.
Lee et al. (2005) note signiﬁcant differences for
alanine/aspartate transaminase and gamma glutamyl
transaminase in blood tests in Gulf War veterans.
NMDA is known to have a trophic effect on cerebellar
granule cells (Caballero-Benitez et al. 2004) and
is known to enhance activity of AAT considerably
(Moran and Rivera-Gaxiola 1992). NMDA may in
turn be modulated by cAMP which is induced by
PACAP (Llansola et al. 2004). PACAP is able to
enhance NMDA receptor function and also enable
RACK1 expression of brain-derived neurotrophic
factor (BDNF) (Yaka et al. 2003). Also, PACAP
helps regulate glial glutamate transport and meta-
bolism (Figiel and Engele 2000). Hence, loss or
compromise of function of PACAP would be expected
to have signiﬁcant effects on NMDA and neuronal
function.
Intra- and extra-cellular calcium regulation appears
to be vital in VN function. Dziema and Obrietan
(2002) note that PACAP potentiates L type Ca(2þ)
activity. Suprachiasmatic nucleus neurons become
sensitive to glutamate only after PACAP adminis-
tration, suggesting that PACAP sets the lower
concentration threshold required for glutamate to
initiate a robust rise in postsynaptic cytosolic Ca(2þ).
Modulatory actions of PACAP are related to the
p42/44 mitogen activated protein kinase (MAPK)
signal transduction cascade. Aoyagi and Takahashi
(2001) note that PACAPenhances Ca(2þ) dependent
glutamate neurotransmitter release in PC12 cells by
modulating steps subsequent to Ca(2þ) entry and
Chen et al. (2000) note that ATP increases Ca(2þ)b y
mobilising internally stored Ca(2þ) followed by an
inﬂux of Ca(2þ). Defer et al. (2000) note that AC is
tissue speciﬁc particularly in relation to Ca(2þ)/-
calmodulin functions and that signals received by
GPCRs can be differentially integrated. Calcium
regulated by VNs thus plays a key role in coordinating
cellular and neurotransmission functions (Endoh
2004).
Receptor function including AC is vital in coordi-
nated and integrated VN activity. Nowak and Zawiska
(1999) note that the plethora of GPCRs and the
functional differentiation of G-protein subunits and
many AC isoforms permit a very complex signaling
system with a wide variety of integrative characte-
ristics. Chabardes et al. (1999) note AC types 5 and
6 constitute a sub-family having the property of being
inhibited by submicromolar Ca2þ concentrations
in addition to Galpha(i)-mediated processes. This
ensureswide responsesin cAMP synthesis.Mons et al.
(1999) note AC types 1 and 8 stimulate Ca2þ/
calmodulin in the hippocampus and this suggests a
role for hippocampus related memory function.
Chern (2000) notes that AC isoenzymes are tightly
controlled by various signals and one of their most
important impacts is on the complexity and ﬁne-tuning
of cellular signaling especially in the CNS where
multiple signals constantly occur. MAP kinase and
CREB mechanisms may also become disrupted result-
ing in signiﬁcant neuro-physiological impairment.
Hippocampal functions such as long-term potentiation
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with PACI-R in presynaptic cells (Otto et al. 1999)
suggesting their vulnerability to VN dysfunction.
Shaked et al. (2005) note that T cells reactive to
CNS-speciﬁc self-antigens protect neurons against
glutamate toxicity. Antigen-speciﬁc autoimmune T
cells increase the ability of microglia-enriched cultures
to remove glutamate. This up-regulation of glutamate
uptake induced by IFN-gamma activation is not
accompanied by the acute inﬂammatory response seen
in LPS-activated cultures. Hence, T cells or their
cytokines can cause microglia to adopt a phenotype
that facilitates rather than impairs glutamate clearance
to contribute to restoration of homeostasis.
Rangon et al. (2005) note that VIP has a protective
effect for glutamate acting via the VPAC2 receptor.
Similarly, Shintani et al. (2005) note PACAP mRNA
levels were increased up to 3.5 £ 8h after glutamate
exposure in rat neuronal cultures indicating a
neuroprotective role of PACAP. Moreover, others
(Dong et al. 2000, Kopp et al. 2001) note the role of
intracellular calcium regulation by PACAP as a
mechanism to control glutamate toxicity in hippocam-
pal and suprachiasmatic neurons. Glutamate trans-
porters have a vital role in clearing glutamate from the
extracellular environment and absorbing it via astro-
cytes to protect neurons from toxicity (Onoue et al.
2002) and these transporters are potently activated by
PACAP (Schluter et al. 2002, Figiel et al. 2003).
As noted above, PACAP plays a critical role in
protecting tissues from hypoxia. Rabl et al. (2002)
note that turtles have much greater levels than
mammals to protect them from diving induced
hypoxia. The gaseous neurotransmitters NO and CO
play vital roles in cellular metabolism and are tightly
regulated by VNs to preserve homeostasis. These
gaseous transmitters are postulated to be associated
with SIDS because of their known association with
cigarette smoking (Staines 2004b). Martinez et al.
(2005) also note the role of the PAC1 receptor in NO
signaling and septic shock. Hence, VNs have complex
and crucial regulatory functions of gaseous neuro-
transmitters and may include NO, CO and ammonia.
Insulin activity is signiﬁcantly modulated by VNs
through AC and cyclic AMP/PKA pathways (Rado-
savljevic et al. 2004). PACAP potently enhances
glucose-stimulated insulin secretion in pancreatic
islets and enhances insulin action in adipocytes
(Nakata et al. 1999). Hence, PACAP and VIP play a
signiﬁcant role in neuroendocrine regulation of
insulin-glucose homeostasis (Wei and Mojsov 1996)
and the PAC1 receptor is required to maintain normal
insulin secretory responsiveness to glucose (Jamen
et al. 2000). CFS patients display signiﬁcantly lower
ACTH response levels in stress testing and insulin
tolerance tests (ITT) (Gaab et al. 2002) as well as
reporting subjective hypoglycaemia. VN dysregulation
may account for these problems (Shintani et al. 2003).
CPG and heat shock proteins may have
important roles in vasoactive neuropeptide
immune dysregulation
Cytosine-guanine dinucleotide fragments (CpG) of
DNA are postulated to be the active ingredients in
bacterial extracts able to induce immune responses
includingadjuvanteffectsandmayhaveapplicationsin
human vaccines (Krieg et al. 1995, Ada and Ramshaw
2003, Tsuchiya et al. 2005). The immune activating
effects of CpG may occur through acquired bacterial
or viral DNA, oligodeoxynucleotide (ODN) or
through self-derived DNA fragments and may have a
role in other autoimmune conditions such as systemic
lupus erythematosus (SLE) (Krieg 1995, Jones et al.
2002, Januchowski et al. 2004). They rescue B cells
from apoptosis, suggesting an autoimmune role
(Yi et al. 1999).
Microbial pathogens containing CpG fragments are
known to bind Toll-like receptors and/or stimulate
microbe-speciﬁc T cells to express CD40 ligand,
thereby licensing antigen presenting cells that bear
both microbial and auto-antigens to break tolerance
and precipitate autoimmune disease (Ichikawa et al.
2002, Ebert et al. 2005). In lupus-prone mice,
abnormal innate responses through their pattern-
recognition TLR9 receptors implies that response to
infectious danger in these mice is inappropriate and
may be linked to lupus pathogenesis (Krieg 1995,
Lenert et al. 2003). Hence, autoimmune and
inﬂammatory processes are known to be induced
through these mechanisms.
HSPs may also be implicated in the recognition of
bacterial or mammalian CpG DNA by acting as a
ligand transfer molecule and/or play a central role in
the signalling cascade induced by CpG DNA
(Bandholtz et al. 2003). Moreover, innate and
adaptive immune mechanisms may act through a
cross priming adjuvant mechanism to engage heat
shock protein in autoreactive responses (Kumaraguru
et al. 2003). HSPs also activate Toll-like receptors in
triggeringinnateimmunity,perhapsthroughadjuvant-
like signals (van Eden et al. 2003, Millar et al. 2003).
HSPs thus have an established place in regulation of
the immune response (Pockley 2003). HSPs also bind
with other antigenic peptides to form immunostimu-
latory complexes (Srivistava 2002) and interestingly
may take the role of antigenic presentation and
processing in immunoprotected regions such as the
central nervous system (Oglesbee et al. 2002). Indeed
aberrant self HSP expression may lead to enhance-
ment/modulation of autoimmune responses in the
context of myelin basic protein and MHC class II type
interactions (Mycko et al. 2004).
As noted above mammalian DNA normally has
lower than predicted CpG dinucleotide fragments and
these are also usually methylated (Shiota 2004). These
characteristics differ from bacterial and viral DNA
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and these are more likely to be hypomethylated,
providing a biological “friend or foe” identiﬁcation
system.
Ancient DNA sequences mimicking bacterial and
viral genomes containing higher proportions of CpG
elements have become incorporated into mammalian
DNA as human endogenous retrovirus (HERV).
These genetic components have become methylated
over time making them mostly benign components of
mammalian DNA. However, these DNA components
may undergo hypomethylation through a range of
stimulating factors, making them able to regulate
transcriptional activity and expression of the HERV
family (Lavie et al. 2005) with implications for a range
of pathologies. Interestingly promoter regions of the
secretin receptor gene have high CpG representation
(Lee et al. 2004) which may also be a feature of
PACAP and VIP receptor genes.
Spontaneous hypomethylation of susceptible
endogenous CpG sequences, or exposure to exogen-
ous bacterial CpG DNA and subsequent stimulation
of cellular processes may mediate innate and acquired
immune pathways including class switching from IgM
to more pathogenic IgG immunoglobulin types (He
et al. 2004). IgM and IgG reactivity to key fragments
of certain VNs or related HSPs thus might theoreti-
cally occur. Such postulated mechanisms could
establish perverse autoreactive loss of immunological
tolerance and effectively create immunisation against
these VNs. The known susceptibility of CpG
fragments to hypomethylation from toxic causes
such as biological poisons and radiation might
predispose to the development of these and other
pathologies (Chen et al. 2004, Pogribny et al. 2004).
These mechanisms might also link fatigue-related VN
autoimmune disorders to exposure to radiological,
biological and chemical warfare agents, extending the
context of public health and military medicine
importance of these postulated disorders.
Therapeutic and preventive interventions
The development of therapeutic and preventive
strategies for postulated VN autoimmune conditions
will be determined by the complex pathophysiology
underpinning them. Mostly these strategies relate to
restoring the functional characteristics ofVNs possibly
compromised (Staines 2005c). Analogies with other
illnesses may provide therapeutic parallels. Some
speculative possibilities are listed below:
Substitution/replacement
Simple substitution/replacement interventions are the
most obvious, however, a signiﬁcant theoretical
impediment is the propensity of these substances to
induce tachyphylaxis (Whalen et al. 1999). Feedback
signaling of VNs is thought to be quite complex and
cascade effects are still largely unpredictable. Catalytic
antibody self-regulatory activity occurs for VNs,
although little is known about how extensively self-
regulation occurs.Catalytic activityofthese antibodies
has been described as an innate function originating
over the course of phylogenetic evolution as opposed
to somatic processes (Gololobov et al. 1999).
Because of rapid natural degradation of VNs, e.g. by
naturally occurring antibodies and hydrolysis, liposo-
mal therapeutic vehicles are being explored to prolong
their biological effects. Sterically stabilised liposomes
(SSL) are being developed to provide long acting
formulations of VIP resistant to the rapid degradation
usually observed (Sethi et al. 2005).
Plasma exchange
Perverse immunological memory in early B cell clones
may also be an important factor in establishing basic
autoimmune pathology. While traditionally viewed as
the line of humoral defence, B cell activation is
increasingly being associated with T cell lineage
development and cellular immune responses. Hence,
B cells as therapeutic targets have increasing potential
in autoimmune disorders (Looney et al. 2004).
Speciﬁc mono- and polyclonal catalytic antibody
generation may provide opportunities for targeting
abnormal autoimmune epitopes in treatment. Circu-
lating T and B cells and immunoglobulins could be
ﬁltered and pathogenic cells and antibodies removed.
This may provide a screening and potentially
therapeutic approach to prevent SIDS and other
fatigue-related disorders, but is not established.
Analogues with MG treatment
The known association of VPAC2 receptors with
acetylcholine and muscle function (Hinkle et al. 2005)
suggests a patho-mechanism crudely analogous with
autoimmune dysfunction in MG and may provide a
useful model to explore. Hence treatment options
such as pyridostigmine and thymectomy may be
considered. In a series of three case reports,
Kawamura et al. (2003) describe successful use of
oral pyridostigmine in the treatment of CFS. This is
an interesting ﬁnding given the possible association of
pyridostigmine with the aetiology of GWS (Abou-
Donia et al. 2004, Staines 2005b). Should speciﬁc
anti-VN T cells from thymus prove to be associated
with GWS and CFS, thymectomy could be con-
sidered. However, given that antigen in GWS and
CFS may indeed be VNs or their receptors and related
HSPs widely distributed throughout the body such a
proposed solution does not immediately appear
rational. Corticosteroids are used judiciously with
MG but may not yet be justiﬁed in postulated VN
autoimmune fatigue-related conditions.
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Should calcium channelopathy prove to be a
signiﬁcant element in VN autoimmune disorders,
parallels with LES may prove useful. Hence calcium
channel promoters, acetylcholinesterases, immune
suppressants, plasma exchange and intravenous
immunoglobulins may be considered in this context.
Anti-idiotype antibodies
Should fatigue-related disorders be found to result
from immune responses to VNs or their receptors
there may be scope to develop anti-idiotype anti-
bodies. While theoretically a possibility, there are no
close analogues of these disorders in which this
treatment is effective. Because of the known associa-
tion of the VPAC2 receptor with acetylcholine activity
as noted above, MG may be a crude analogue
inasmuch as acetylcholine receptors are compromised
albeit by a different mechanism. However, anti-
idiotype antibody treatment in MG is of equivocal
effectiveness. Alternatively should self antibodies to
VN regulatory mechanisms be the causative mechan-
ism these could be extracted by plasma exchange or
speciﬁc anti-idiotype antibodies.
Epigenetic DNA modiﬁcations
T- and B-cell functioning may be inﬂuenced by VNs
through selective screening of speciﬁc epitope carriers.
While this research is still in its infancy, potentially VN
analogous autoimmune conditions such as SLE may
shed light on new CpG therapeutic technologies
(Januchowski et al. 2004). Targeting genomic
expression abnormalities may also be possible through
therapeuticCpGimmunostimulatingand immunosup-
pressive technologies. Genomic modiﬁcation of VN
expression may be relevant in SIDS should respiratory
control deﬁcits be proven to play a causal role.
Moreover, CpG binding proteins in microglia are
mostlyRNAprocessingenzymessuggestingaprofound
array of opportunities by which CpG may inﬂuence
cellular processes in the CNS (Zhang et al. 2005).
CpG and DNA vaccines
Prevention of possible VN autoimmune fatigue related
disorders may be important areas for future develop-
ment. Immunoprotective CpG DNA fragments may
be applied as vaccines to protect VNs or their
receptors from degradation or dysfunction. Beneﬁcial
natural immunity against pro-inﬂammatory cytokines
may also be ampliﬁed by DNA vaccines (Karin 2004)
although these will need to be developed with care
(Klinman et al. 2003). Strategies to prevent or treat
VN autoimmune disorders may include active and
passive vaccination to protect VN receptors from
direct immunogenic or indirect molecular mimicry
effects. The underlying principle for vaccination
would be to protect those at risk from neurological
autoimmune dysfunction. However, this approach
would be complex and criteria for being at risk would
need to be identiﬁed. To speculate, a vaccine for SIDS
may be theoretically possible based on protecting vital
VN function from disruption at critical stages in infant
development.
Novel neuroprotective agents
Novel small peptides with stress-protein-like
sequences have been identiﬁed which exhibit strong
levels of neuroprotection. These proteins protect
neurons from cell death associated with electrical
activity and heat shock protein antibodies and, there-
fore, may play a role in the treatment of neurodege-
nerative diseases. Therapeutic strategies for a range of
neuroprotective substances including members of the
VIP/PACAP family are also suggested (Brenneman
and Gozes 1996, Gozes and Divinski 2004).
Preservation of function by other substances
regulated by VNs may also be considered. For
example, CSF endogenous opioid substances are
regulated by PACAP and these have a role in cerebral
arterial responses to hypoxia (Wilderman and Arm-
stead 1997), which in turn may be relevant to
protection from SIDS. Endogenous pain mediation
may play a signiﬁcant role in these conditions and
restoration of this function may be appropriate if
shown to be attributed to VN dysfunction (Julien et al.
2005). Finally, mutually enhancing “cross-over”
effects of VIP/PACAP functioning may suggest that
therapeutic interventions may have synergistic ben-
eﬁts with these substances (Samborski et al. 2004).
Drug treatments
Pharmaceuticals such as anti-depressants have been
shown empirically to provide symptomatic relief to
some fatigue-related disorders. These conditions have
been shown not to be primary organic depression but
may be explained as collateral symptomatology to
possible VN autoimmune dysfunction.
Blockade of 5-HT could elicit symptomatology
consistent with a VN autoimmune disorders. This
effect may be explained by the role of serotonin in
controlling VIP release mechanisms. Altered VIP
expression may occur prenatally through serotonin
imprinting in ontogenesis (Mirochnik et al. 2003)
suggesting implications for monitoring the use of
selective serotonin uptake inhibitor (SSRI) and tri-
cyclic anti-depressants in pregnancy. However,
decreased 5-HT1A receptor numbers and afﬁnity
are noted in CFS particularly in the hippocampus
(Cleare et al. 2005) possibly indicating heterogenous
modulating relationships between VIP and 5-HT
receptors in CFS. Chloroquine may also have a role in
treatment or prevention (Hong et al. 2004).
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Because of the likely cAMP disruption in these
conditions, cAMP promoting agents such as phos-
phodiesterase inhibitors may have a role (Staines
2006). Drugs such as rolipram, a phosphodiesterase
type 4 inhibitor, activate cAMP-response element
binding proteins (CREB) signalling as well as
enhancing cAMP levels by impeding cAMP catabo-
lism (Conti and Blendy 2004). Imipramine also
appears to have a key role in cAMP metabolism and,
therefore, may be useful in combination drug therapy
(Itoh et al. 2004, Knuuttila et al. 2004). Rolipram was
developed as an anti-depression drug but has been
found also to have anti-inﬂammatory and immuno-
regulatory activities (Sommer et al. 1995, Abbas et al.
2000). Unfortunately, side-effects such as nausea,
vomiting and headache are reported suggesting the
need for less side effect-inducing analogues in therapy
(Xu et al. 1999) and continuous administration may
be necessary to sustain its therapeutic effect (Martinez
et al. 1999). Later-generation drugs of this family may
prove to have better tolerance.
Conclusion
The autoimmune hypothesis of VNs suggests that
relatively minor infection or inﬂammation results in
predictable pro-inﬂammatory cytokine and other
responses which may have subsequent serious effects
involving VN dysfunction. Other pro-inﬂammatory
effects such as NO release and possible chemical
sensitivities may also result. Modulation and termina-
tion of these inﬂammatory responses is required by
VNs. Autoimmune effects, e.g. on PACAP/VIP or the
PAC1/VPAC1/VPAC2 receptors will have a negating
effect on VN function and also subsequent effects on
intracellular mechanisms.
While some inﬂammatory or infectious events may be
trivial, compromise of the functions of VNs such as
PACAP/VIP/CGRP is not. Brain, cardiac and other
organs known to exhibit similar PACAP/VIP receptor
function would also be expected to demonstrate
dysfunction somewhat simultaneously. Prevention of
SIDS and other disorders if shown to be VN
autoimmuneconditionsmayevolvefromtheseconcepts.
Public health implications may exist if “epidemics”
or simply seasonal circulating organisms have particu-
lar molecular mimicry with VNs or their receptors.
Short term relatively benign IgM may shift to a more
pathogenic IgG phenotype as autoimmune responses
to VNs/receptors and result in longer-term profound
impairment and disability. These VN autoimmune
processes may also have implications for military
medicine where radiological, chemical and biological
agents may play an important role in pathogenesis.
Postulated autoimmune VN conditions may share a
common pathophysiology in contributing to apoptosis
of neuronal and other vital neurological cells and that
this underpins failure or compromise of important
neuroregulatory mechanisms. Perhaps paradoxically,
necessary apoptosis of autoreactive immunological
cells, e.g. B and plasma cells may not occur and this
predisposestoautoimmunedysfunctionofVNsor their
receptors. Dysregulation of innate immune systems
through CpG and TLR9 interactions may also prove to
have important roles in establishing autoreactivity.
Further understanding of possible autoimmune
dysfunction of these VNs and their receptors may
elucidate the mechanisms of disabling fatigue-related
syndromes such as CFS and GWS, and possibly
SIDS, and open the way for routine laboratory
investigations and prevention options. VN and
receptor reactivation may prove to become successful
interventions. A spectrum of interventions including
genomic, immunological and biochemical/drug thera-
pies may prove to be possible in VN autoimmune
fatigue-related disorders. Interventions such as phos-
phodiesterase inhibitors, immunotherapy, VN repla-
cement or VN receptor reactivation may prove to be
useful in these conditions but are not yet tested.
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